Stanford University
Showing 21-30 of 80 Results
-
Bita Fakhri, MD, MPH
Assistant Professor of Medicine (Hematology)
BioDr. Bita Fakhri is Assistant Professor of Medicine in the Division of Hematology at Stanford University School of Medicine. She specializes in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), hairy cell leukemia, and other hematologic malignancies. As a clinical scientist, Dr. Fakhri is dedicated to caring for patients, teaching trainees, and researching novel therapies for patients with CLL/SLL. Dr. Fakhri has co-authored numerous publications on topics including CLL, novel targeted agents, and cellular therapies for patients with hematologic malignancies. Currently, Dr. Fakhri is the director of the CLL clinical trial portfolio at Stanford. Additionally, in her role as the DEI ambassador of the Division of Hematology, her main focus is to enhance trial equity among underserved and marginalized populations in the Stanford catchment area.
-
Jason Gotlib
Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs -
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
Ruwan Gunaratne
Instructor, Medicine - Hematology
BioRuwan Gunaratne, MD, PhD is an Instructor in Hematology at Stanford University School of Medicine and a board-certified hematologist-oncologist with a clinical focus on acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). His clinical and translational research centers on improving disease monitoring in myeloid cancers using personalized circulating tumor DNA (ctDNA) profiling, a blood-based approach designed to more sensitively track measurable residual disease (MRD), assess treatment response, refine risk stratification, and detect relapse earlier across the myeloid disease spectrum. Dr. Gunaratne’s work has been recognized with awards from the American Society of Hematology and the Stanford Cancer Institute, and he is actively committed to advancing precision medicine approaches for patients with myeloid malignancies.
